Comverse option probe worries analysts

Merrill Lynch cited similar concerns and downgraded the shares to "neutral" from "buy."

March 16, 2006 07:00
2 minute read.
comverse logo 88

comverse logo 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Analysts reacted with concern Wednesday to Comverse Technology's announcement that it may restate its financial results due to questions surrounding the accuracy of the dates on its option grants. "One of the principle concerns for the stock is that uncertainty with regards to what is being investigated, how long it takes and how long it will be an overhang on the shares," said Robert W. Baird analyst William Power, who downgraded the shares to "neutral" from "outperform." "It has the potential to drag on, especially if the SEC chooses to investigate which is unclear at this stage." Earlier this week, Comverse said it had convened a special committee of its board of directors to review matters relating to its stock option grants, and delayed publishing its 2005 end of year earnings, which had been scheduled for release Wednesday. "Comverse had not been expensing the options and intended to start recording the expense in this fiscal year," said Power, who does not own any Comverse stock. "What they had done is disclose in their SEC filing what their potential impact would be if they had been included." Whatever possible restatements would occur, he said it seems it won't result in restating past earnings but could result in restating some of the previously made predictions. "Until we get more clarity for further resolution to the investigation, it will be difficult for the stock to move forward. Our net view is that we expect it to trade in a pretty tight range now," Power said. Merrill Lynch cited similar concerns and downgraded the shares to "neutral" from "buy." "We suspect that the investigation relates to in-the-money options granted in the mid-to-late 90s but which were misreports as 'at-the-money' in order to avoid related expenses," Merrill Lynch analyst Tal Liani wrote in a note to clients. Liani, however, noted that regardless of the option issue, the company continues to "execute well." In its preliminary earnings, released at the same time it made the options announcement, Comverse said it had sales of $337 million in the fourth quarter of 2005, its 13th successive quarter of revenue growth, and ended the quarter with a record backlog of orders of $798m. Standard & Poor's, meanwhile, on Wednesday put the company's corporate credit and senior unsecured debt on CreditWatch with negative implications, meaning it could be downgraded. Other analysts, though expressing concern over the options issue, remained upbeat about the company's outlook, however. "We are maintaining our 'Positive' rating based on excellent core business fundamentals," Susquehanna Investment group said in its review of the company. "Our view assumes Comverse's accounting issues are restricted to non-cash option grants, which we hope will be resolved by May 1."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection